HIV entry inhibition by the envelope 2 glycoprotein of GB virus C.
Epidemiological studies have revealed an association between GB virus C (GBV-C) long-term viraemia and ameliorated HIV disease progression. We have provided evidence that a single protein of GBV-C, the glycoprotein E2, interferes with early HIV replication steps of both X4- and R5-tropic HIV strains. Preincubation with anti-E2 antibody specifically abrogates the inhibitory effect. Results were confirmed by the in-vitro expression of GBV-C E1/E2 encoding RNA.
Jung
Susan
S
Institute of Clinical and Molecular Virology, University Hospital of the Friedrich-Alexander-Universität, Erlangen-Nuremberg, Germany.
Eichenmüller
Melanie
M
Donhauser
Norbert
N
Neipel
Frank
F
Engel
Alfred M
AM
Hess
Georg
G
Fleckenstein
Bernhard
B
Reil
Heide
H
D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D029407:GB virus C / Q000502:physiology; D015658:HIV Infections / Q000821:virology*; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D014162:Transfection; D014759:Viral Envelope Proteins / Q000235:genetics / Q000494:pharmacology / Q000502:physiology*; D014779:Virus Replication / Q000187:drug effects / Q000502:physiology*
D011993:Recombinant Fusion Proteins; D014759:Viral Envelope Proteins; C107619:glycoprotein E2, GB virus C